Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject's parent(s)/ legally acceptable representative(s) (LAR\[s\]) who, in the opinion of the Investigator, can and will comply with the requirements of the protocol (e.g. availability for Diary Card completion, return for follow-up visits, availability for clinical follow-up throughout the study period).~* Written/ thumb printed informed consent obtained from the subject' parent(s)/ LAR\[s\] prior to performing any study specific procedure. In addition, written/ thumb printed in-formed assent should be obtained if appropriate (from all subjects aged 13 to 17 years and from younger subjects as per local requirements).~* A male or female child aged 1 to 17 years inclusive at the time of Screening.~* Subjects with a negative RDT test for Malaria within 30 days prior to randomisation into the study.~OR Subjects with a positive RDT test for Malaria who completed antimalarial treatment at least 5 days prior to randomisation into the study.~* Healthy subjects as per Investigator judgement, as estab-lished by medical history, clinical examination and haema-tology/ biochemistry laboratory parameters screening be-fore entering into the study.~* Female subjects of non-childbearing potential may be enrolled in the study.~  * Non-childbearing potential is defined as pre-menarche or ovariectomy.~* Female subjects of childbearing potential may be enrolled in the study, if the subject:~  * has practiced adequate contraception for 30 days prior to the Day 0 visit, and~ * has a negative pregnancy test at the Day 0 visit, and~ * has agreed to continue adequate contraception until 30 days after the Month 6 visit~Exclusion Criteria:~* Child in care.~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine during the period starting 30 days before the Day 0 visit, or planned use during the study period.~* Previous vaccination with an investigational EBOV or Marburg vaccine, or previous vaccination with a chim-panzee adenoviral vectored investigational vaccine.~* Known prior EBOV or SUDV disease.~* Travel to country affected by the EBOV epidemic or direct contact with person with EVD within 21 days prior to the Day 0 visit.~* History of any reaction or hypersensitivity (such as ana-phylaxis, urticaria (hives), respiratory difficulty, angioe-dema, or abdominal pain) likely to be exacerbated by any component of the study vaccine.~* Planned administration/ administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after each vaccination visit.~* Acute or chronic illness determined by medical history, clinical examination and laboratory screening tests in-cluding, but not limited to:~* Clinically significant immunosuppressive or immunodeficient condition (e.g. clinical acquired immune deficiency syndrome \[AIDS\]).~* Major congenital defects.~* Malnutrition (defined as weight for age Z-score less than -3, or other clinical signs of malnutrition).~* Any clinically significant haematological or biochemical laboratory abnormality.~* Pregnant female.~* Any condition that in the Investigator's opinion may po-tentially compromise subject safety or interfere with sub-ject assessment or compliance.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- GSK3390107A+Nimenrix Group (Type: EXPERIMENTAL): Subjects in the GSK3390107A+Nimenrix Group received the investigational GSK3390107A vaccine at the Day 0 visit and Nimenrix at the Month 6 visit, intramuscularly into the deltoid region, or thigh region for smaller children.
- Nimenrix+GSK3390107A Group (Type: EXPERIMENTAL): Subjects in the Nimenrix +GSK3390107A Group received Nimenrix at the Day 0 visit and the investigational GSK3390107A vaccine at the Month 6 visit, intramuscularly into the deltoid region, or thigh region for smaller children.

Based on this trial design, predict the completion outcome and termination type (if applicable).